230 related articles for article (PubMed ID: 31451229)
1. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
2. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
J Int Med Res; 2020 Oct; 48(10):300060520964659. PubMed ID: 33111612
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
[No Abstract] [Full Text] [Related]
4. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
Mangia A; Scaglione F; Toniutto P; Pirisi M; Coppola N; Di Perri G; Alvarez Nieto G; Calabrese S; Hernandez C; Perrone V; Degli Esposti L; Fagiuoli S
Int J Environ Res Public Health; 2021 Jul; 18(13):. PubMed ID: 34281080
[TBL] [Abstract][Full Text] [Related]
5. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).
Fagiuoli S; Toniutto P; Coppola N; Ancona DD; Andretta M; Bartolini F; Ferrante F; Lupi A; Palcic S; Rizzi FV; Re D; Alvarez Nieto G; Hernandez C; Frigerio F; Perrone V; Degli Esposti L; Mangia A
Ther Clin Risk Manag; 2023; 19():57-65. PubMed ID: 36699017
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
Adicciones; 2022 Nov; 34(4):279-284. PubMed ID: 33338248
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
Gordon S; Lee J; Smith N; Dieterich D
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):251-257. PubMed ID: 31204882
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
[TBL] [Abstract][Full Text] [Related]
9. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
10. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
[TBL] [Abstract][Full Text] [Related]
11. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
[TBL] [Abstract][Full Text] [Related]
12. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Pearlman BL; Hinds AE
Aliment Pharmacol Ther; 2018 Nov; 48(9):914-923. PubMed ID: 30288771
[TBL] [Abstract][Full Text] [Related]
13. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
[No Abstract] [Full Text] [Related]
15. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
[TBL] [Abstract][Full Text] [Related]
17. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
18. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
Langness JA; Nguyen M; Wieland A; Everson GT; Kiser JJ
World J Gastroenterol; 2017 Mar; 23(9):1618-1626. PubMed ID: 28321163
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
Vermehren J; Peiffer KH; Welsch C; Grammatikos G; Welker MW; Weiler N; Zeuzem S; Welzel TM; Sarrazin C
Aliment Pharmacol Ther; 2016 Oct; 44(8):856-65. PubMed ID: 27549000
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]